( LAWRENCEVILLE N.J.--(BUSINESS WIRE)--A...)Onconova Therapeutics Announces Presentation of Clinical and,Non-Clinical Results for Its Lead Compound ON 01910.Na at American,Association of Cancer Research Conference in Los Angeles,Health

LAWRENCEVILLE, N.J.--(BUSINESS WIRE)--Apr 16, 2007 - Onconova Therapeutics, Inc. today announced the presentation of several scientific studies relating to its lead anticancer drug ON 01910.Na at the Annual Meeting of the American Association for Cancer Research (AACR) being held April 14-18, 2007 in Los Angeles, California. During this meeting, on Sunday, April 15th, Dr. E. Premkumar Reddy, the scientific founder of Onconova was honored as the recipient of the 2006-2007 Society of Asian American Scientists in Cancer Research Award for his fundamental contributions to cancer research.

Data presented in oral and poster sessions will focus on pre-clinical and clinical studies with ON 01910.Na, a novel, targeted, small-molecule anti-cancer compound undergoing multiple clinical trials at several major clinical centers in the USA and abroad. ON 01910.Na has shown broad-spectrum anti-tumor activity against both solid tumors and hematological malignancy in pre-clinical studies, and has demonstrated synergistic activity when combined with several classes of conventional chemotherapeutic agents. The Company is planning multiple Phase 2 and combination Phase I clinical trials with leading investigators at major oncology clinical centers in the USA.

The antitumor activity of ON 01910.Na in combination with Eloxatin(R) (Sanofi-Aventis) is demonstrated in a poster presentation entitled, "ON 01910.Na enhances the in vivo cancercidal effects of Oxaliplatin" by J. Jiang, Y. Li, L. Wang, J. Qu, P. Mannam, E. P. Reddy and James F. Holland (Mount Sinai School of Medicine, New York). Employing a nude mouse model system and human liver, hormone refractory prostate, melanoma, pancreatic and colon tumors, single agent activity of ON 01910.Na was shown for all tumor types tested and this effect was enhanced by combining with Oxaliplatin in the liver, prostate and melanoma tumor models. ON 01910.Na was well tolerated in all case
'"/>

Page: 1 2 3
Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care